Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria - Slideshow

SignalsMonitor is following this as a markets story. Seeking Alpha is the outlet attached so far. The first report grouped here was at 21 Sept 2026, 15:08 UTC. 4 material updates are listed in the timeline. The headline in use is “Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria - Slideshow”. This note is SignalsMonitor's own briefing, not the publisher's article.